eli lilly new glp 1 Novo, weight-loss drugs should be first option obesity treatments, European doctors say Lilly's triple-acting obesity drug hits

Molecular Cell Biology 2022

Support - Our bodies' glutathione levels decline with age

Their primary mechanisms of action include: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, which helps lower blood sugar levels with a low risk of hypoglycaemia when used alone (though risk increases when combined with insulin or sulfonylureas) Suppressing glucagon release from pancreatic alpha cells, reducing hepatic glucose production Slowing gastric emptying , which prolongs the feeling of fullness after meals Acting on appetite centres in the brain , particularly the hypothalamus, to reduce hunger and food intake These combined effects result in improved glycaemic control for people with diabetes and significant weight loss

Zealand is also investigating a drug targeting amylin which they think could be used in co-formulation with other peptides including GLP-1

Initially, intra-islet GLP-1/GLP-1R signaling partially decreased the palmitate-induced damage to cells